By Tag Clar Editorial
In a sudden and controversial change, the cabinet has decided to amend its health law. These reforms will reduce the financial burden on families regarding health insurance and ancillary costs, while placing greater pressure on the government and especially on the pharmaceutical industry.
Why Were These Changes Made?
This decision was made on the eve of the final approval of the new law and reflects the government's effort to improve the financial situation of families and increase support for them against health costs. However, there are concerns about the new pressures on the pharmaceutical industry and consequently, on drug prices and access to treatment.
It seems that these changes are in response to public criticisms and protests regarding the high costs of treatment and medication. Nevertheless, many questions remain about the long-term effects of these decisions on the quality of health services and the financial status of the pharmaceutical industries.
